Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Active, not recruiting · NCT03891784 · Registry updated 2026-01-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenoma, digestive system neuroendocrine neoplasm, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, pancreatic neuroendocrine tumor | Active, not recruiting | Phase 2 | 2026-01-14 | NCT03891784 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| University of Washington | 397 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | United States | 140 |
| University of Colorado | Denver | United States | 1 |